1. Indications:

Olakin (Olaparib) 150 mg is indicated for the treatment of:

• Advanced ovarian cancer in patients with deleterious or suspected deleterious germline or somatic BRCA-mutated epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with three or more prior lines of chemotherapy.
• Germline BRCA-mutated, HER2-negative metastatic breast cancer, previously treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting.
• Germline BRCA-mutated, metastatic castration-resistant prostate cancer, previously treated with enzalutamide or abiraterone.

2. Pharmacology:

Olakin (Olaparib) 150 mg exerts its pharmacological effects by selectively inhibiting the activity of poly (ADP-ribose) polymerase (PARP) enzymes, particularly PARP-1 and PARP-2. By inhibiting PARP, Olakin prevents the repair of single-strand DNA breaks in cancer cells, leading to the accumulation of DNA damage and eventual cell death, particularly in cells with defective DNA repair mechanisms, such as those with BRCA mutations.

3. Dosage and Administration:

The recommended dosage of Olakin (Olaparib) 150 mg may vary depending on the type of cancer being treated and individual patient characteristics. Typically, the prescribed dose is 150 mg taken orally twice daily, with or without food. Treatment should continue until disease progression or unacceptable toxicity occurs. Dose adjustments or discontinuation may be necessary based on individual patient response and tolerability.

4. Interaction:

Olakin (Olaparib) 150 mg may interact with other medications, including:

• Strong CYP3A inhibitors or inducers: Co-administration with drugs that affect CYP3A metabolism may alter the plasma concentration of Olakin.
• P-glycoprotein (P-gp) substrates: Olakin may increase the plasma concentrations of drugs that are substrates of P-gp, potentially leading to increased toxicity.

Patients should inform their healthcare provider about all medications they are taking, including prescription, over-the-counter, and herbal products, to avoid potential interactions.

5. Side Effects:

Common side effects associated with Olakin (Olaparib) 150 mg may include:

• Nausea
• Fatigue
• Anemia
• Diarrhea
• Loss of appetite
• Vomiting

Patients should report any persistent or severe side effects to their healthcare provider for further evaluation and management.

6. Precautions and Warnings:

Before using Olakin (Olaparib) 150 mg, patients should be aware of the following precautions:

• Olakin may cause myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Patients should be monitored for hematologic toxicities during treatment.
• Pulmonary embolism and pneumonitis have been reported with Olakin. Patients should be monitored for signs and symptoms of these conditions.
• Olakin may cause fetal harm if used during pregnancy. Female patients of reproductive potential should use effective contraception during treatment and for at least six months after the last dose.

7. Overdose Effects:

In case of overdose with Olakin (Olaparib) 150 mg, supportive care should be initiated, and symptomatic treatment may be administered as necessary. There is no specific antidote for Olakin overdose, and patients should seek immediate medical attention if overdose is suspected.